ID

31110

Beschreibung

A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00452413

Link

https://clinicaltrials.gov/show/NCT00452413

Stichworte

Versionen (1)
  1. 20.07.18 20.07.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

20. Juli 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-Small Cell Lung Cancer NCT00452413

Englisch

Eligibility Non-Small Cell Lung Cancer NCT00452413

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. phase 1: any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.
Beschreibung

Solid Neoplasm incurable | Systemic therapy Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0280100
UMLS CUI [1,2]
C0175969
UMLS CUI [2,1]
C1515119
UMLS CUI [2,2]
C1265611
phase 2: histologic diagnosis of advanced nsclc, stage iiib with malignant pleural effusion or stage iv per american joint committee on cancer staging criteria for nsclc. patients must have failed 1 or 2 prior systemic treatment regimen(s).
Beschreibung

Non-Small Cell Lung Carcinoma Advanced TNM clinical staging | Pleural Effusion, Malignant | Systemic therapy Quantity failed

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C3258246
UMLS CUI [2]
C0080032
UMLS CUI [3,1]
C1515119
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0231175
2. performance status of 0, 1, or 2 on the eastern cooperative oncology group (ecog) scale
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
3. prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
Beschreibung

Prior Chemotherapy Completed | Toxicity Patient recovered | Exception Alopecia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0205197
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C1115804
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0002170
4. prior radiotherapy is allowed to < 25% of the bone marrow prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
Beschreibung

Prior radiation therapy Bone Marrow Percentage | Prior radiation therapy Completed | Toxicity Patient recovered | Exception Alopecia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C0205197
UMLS CUI [3,1]
C0600688
UMLS CUI [3,2]
C1115804
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0002170
5. non-measurable or measurable disease as defined by recist.
Beschreibung

Disease Non-Measurable | Measurable Disease

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1518373
UMLS CUI [2]
C1513041
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who
Beschreibung

Criteria Fulfill

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
1. are unable to swallow tablets.
Beschreibung

Lacking Able to swallow Tablets

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C2712086
UMLS CUI [1,3]
C0039225
2. unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
Beschreibung

Unable to discontinue Carbamazepine | Unable to discontinue Phenobarbital | Unable to discontinue Phenytoin

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1548265
UMLS CUI [1,2]
C0006949
UMLS CUI [2,1]
C1548265
UMLS CUI [2,2]
C0031412
UMLS CUI [3,1]
C1548265
UMLS CUI [3,2]
C0031507
3. have previously been treated with an epidermal growth factor receptor (egfr) inhibitor, including erlotinib.
Beschreibung

Epidermal growth factor receptor inhibitor | erlotinib

Datentyp

boolean

Alias
UMLS CUI [1]
C1443775
UMLS CUI [2]
C1135135
4. are receiving concurrent administration of any other antitumor therapy.
Beschreibung

Cancer treatment Other

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205394
5. have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
Beschreibung

Drugs, Non-Prescription

Datentyp

boolean

Alias
UMLS CUI [1]
C0013231
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-Small Cell Lung Cancer NCT00452413

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Solid Neoplasm incurable | Systemic therapy Quantity
Item
1. phase 1: any incurable solid malignancy, with no more than 3 prior systemic treatment regimens.
boolean
C0280100 (UMLS CUI [1,1])
C0175969 (UMLS CUI [1,2])
C1515119 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
Non-Small Cell Lung Carcinoma Advanced TNM clinical staging | Pleural Effusion, Malignant | Systemic therapy Quantity failed
Item
phase 2: histologic diagnosis of advanced nsclc, stage iiib with malignant pleural effusion or stage iv per american joint committee on cancer staging criteria for nsclc. patients must have failed 1 or 2 prior systemic treatment regimen(s).
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C0080032 (UMLS CUI [2])
C1515119 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0231175 (UMLS CUI [3,3])
ECOG performance status
Item
2. performance status of 0, 1, or 2 on the eastern cooperative oncology group (ecog) scale
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Completed | Toxicity Patient recovered | Exception Alopecia
Item
3. prior chemotherapy must be completed at least 2 weeks prior to study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
boolean
C1514457 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C1115804 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0002170 (UMLS CUI [3,2])
Prior radiation therapy Bone Marrow Percentage | Prior radiation therapy Completed | Toxicity Patient recovered | Exception Alopecia
Item
4. prior radiotherapy is allowed to < 25% of the bone marrow prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from acute toxic effects (except alopecia) prior to enrollment.
boolean
C0279134 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0600688 (UMLS CUI [3,1])
C1115804 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0002170 (UMLS CUI [4,2])
Disease Non-Measurable | Measurable Disease
Item
5. non-measurable or measurable disease as defined by recist.
boolean
C0012634 (UMLS CUI [1,1])
C1518373 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Criteria Fulfill
Item
patients who
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Lacking Able to swallow Tablets
Item
1. are unable to swallow tablets.
boolean
C0332268 (UMLS CUI [1,1])
C2712086 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,3])
Unable to discontinue Carbamazepine | Unable to discontinue Phenobarbital | Unable to discontinue Phenytoin
Item
2. unable to discontinue use of carbamazepine, phenobarbital, and phenytoin.
boolean
C1548265 (UMLS CUI [1,1])
C0006949 (UMLS CUI [1,2])
C1548265 (UMLS CUI [2,1])
C0031412 (UMLS CUI [2,2])
C1548265 (UMLS CUI [3,1])
C0031507 (UMLS CUI [3,2])
Epidermal growth factor receptor inhibitor | erlotinib
Item
3. have previously been treated with an epidermal growth factor receptor (egfr) inhibitor, including erlotinib.
boolean
C1443775 (UMLS CUI [1])
C1135135 (UMLS CUI [2])
Cancer treatment Other
Item
4. are receiving concurrent administration of any other antitumor therapy.
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Drugs, Non-Prescription
Item
5. have received treatment within the last 30 days with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video